New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
09:21 EDTSUPN, TCAP, CALL, EXAS, ICPT, TIPT, HCLP, SOL, DNDN, ANF, INSY, FRF, FLO, NOAH, CNAT, KATEOn The Fly: Pre-market Movers
HIGHER: Intercept (ICPT), up 46% after upgraded at Leerink and Citigroup following OCA data. Conatus Pharmaceuticals (CNAT), which also develops treatments for liver disease, up 8.5%... Fontegra Financial (FRF), up 40% after Tiptree Financial (TIPT) to acquire the company for $10.00 per share in cash... Insys Therapeutics (INSY), up 15.4% after submiting NDA for new formula of Dronabinol Oral Solution, saying it is on track to submit at least four IND applications with the FDA in the second half of 2014... Exact Sciences (EXAS), up 8% after announcing FDA approved for Cologuard... Abercrombie & Fitch (ANF), up 2.7% after upgraded at Stifel. UP AFTER EARNINGS: Kate Spade (KATE), up 5.5%... Noah Holdings (NOAH), up 3%... ReneSola (SOL), up 5%... Supernus (SUPN), up 14%. LOWER: NII Holdings (NIHD), down 54.5% after warning it needs to make "key decisions" to address liquidity, "likely" to file a voluntary petition for relief under Chapter 11 of the Bankruptcy Code... Dendreon (DNDN), down 23.6% after warning that its alternatives could leave shareholders with no ownership... magicJack (CALL), down 10.3%, downgraded at Canaccord following Q2 results... Hi-Crush Partners (HCLP), down 4.7% after filing to sell 3.26M common units representing limited partners... Triangle Capital (TCAP), down 3.8% after filing to sell 4M shares of common stock. DOWN AFTER EARNINGS: Nuance (NUAN), down 9.4%... Flowers Foods (FLO), down 7.8%.
News For KATE;ANF;ICPT;CNAT;DNDN;EXAS;NOAH;SOL;CALL;FLO;HCLP;TCAP;FRF;TIPT;SUPN;INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
10:48 EDTKATEOptions with increasing implied volatility: PPC KATE AVP
January 26, 2015
10:53 EDTKATEKate Spade volatility elevated into Q4 and outlook
Subscribe for More Information
10:50 EDTKATEOptions with increasing implied volatility: HLSS KATE AVP
Subscribe for More Information
08:11 EDTINSYInsys Therapeutics receives FDA ODD for LEP candidate
Insys Therapeutics announced that the FDA has granted orphan drug designation, or ODD, to its Liposomal Encapsulated Paclitaxel, or LEP, candidate for the treatment of ovarian cancer.
January 23, 2015
10:02 EDTFLOOn the Fly: Analyst Downgrade Summary
Subscribe for More Information
10:02 EDTKATEOn the Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AmSurg (AMSG) upgraded to Overweight from Neutral at Piper Jaffray... Anglo American (AAUKY) upgraded to Neutral from Sell at Goldman... Autobytel (ABTL) upgraded to Buy from Hold at Ascendiant... Charles River Labs (CRL) upgraded to Outperform from Market Perform at William Blair... Chesapeake (CHK) upgraded to Outperform from Neutral at Credit Suisse... CubeSmart (CUBE) upgraded to Buy from Neutral at SunTrust... Cypress Semiconductor (CY) upgraded to Neutral from Underweight at JPMorgan... DreamWorks Animation (DWA) upgraded to Overweight from Neutral at Piper Jaffray... E-Trade (ETFC) upgraded at Credit Suisse... Kate Spade (KATE) upgraded to Buy from Neutral at Mizuho... LinkedIn (LNKD) upgraded to Strong Buy from Market Perform at Raymond James... Matthews (MATW) upgraded to Outperform from Neutral at Macquarie... Meridian Bioscience (VIVO) upgraded to Buy from Hold at Craig-Hallum... Michael Kors (KORS) upgraded to Buy from Neutral at Mizuho... NIC Inc. (EGOV) upgraded to Hold from Sell at Maxim... Natural Grocers (NGVC) upgraded to Overweight from Neutral at Piper Jaffray... Nucor (NUE) upgraded to Buy from Neutral at Goldman... ResMed (RMD) upgraded to Buy from Hold at Needham... Smith & Wesson (SWHC) upgraded to Buy from Neutral at Dougherty... Ternium (TX) upgraded to Neutral from Sell at Goldman... Union Pacific (UNP) upgraded to Buy from Hold at BB&T... ZAGG (ZAGG) upgraded to Buy from Hold at Craig-Hallum... lululemon (LULU) upgraded to Overweight from Neutral at JPMorgan.
09:09 EDTFLOFlowers Foods downgraded to Hold from Buy at BB&T
Subscribe for More Information
08:37 EDTHCLPBofA/Merrill U.S. oil & gas analysts to hold an analyst/industry conference call
Subscribe for More Information
06:37 EDTKATEKate Spade upgraded to Buy from Neutral at Mizuho
Subscribe for More Information
January 22, 2015
11:05 EDTINSYInsys Therapeutics granted orphan status for ovarian cancer treatment
Subscribe for More Information
07:17 EDTICPTIntercept price target lowered to $300 from $500 at Deutsche Bank
Subscribe for More Information
January 21, 2015
16:32 EDTSUPNSupernus sues TWi for infringement of Oxtellar XR patents
Subscribe for More Information
11:23 EDTANFSnow Capital reports 5.1% passive stake in Abercrombie & Fitch
January 20, 2015
16:09 EDTCALLmagicJack announces beta testing on U.S. texting APP and America/Mexico APP
magicJack VocalTec announced that it is in beta testing on two APPs in the U.S. and Mexico, respectively. The magicJack U.S. texting APP is currently in beta testing on iOS by several thousand users and is expected to be made available to customers as soon as testing is completed. In Mexico, the "magicJack America" APP is also currently in beta testing on iOS and Android and is being used by several thousand users.
January 16, 2015
17:04 EDTSUPNSupernus sues Par Pharmaceuticals for patent infringement
Supernus Pharmaceuticals announced that it sued generic drug makers Par Pharmaceutical Companies, and Par Pharmaceutical, collectively known as Par, for infringement of four patents covering its antiepileptic drug Trokendi XR. Supernus' United States Patents Nos. 8,298,576, 8,298,580, 8,663,683 and 8,877,248 cover once-a-day topiramate formulations and methods of treating seizures using those formulations. Patent protection for Trokendi XR expires no earlier than 2027. The complaint, filed in the U.S. District Court for the District of New Jersey, alleges that Par infringed Supernus' Trokendi XR patents by submitting to the FDA an Abbreviated New Drug Application, ANDA, seeking to market a generic version of Trokendi XR prior to the expiration of Supernus' patents. Filing its complaint within 45 days of receiving Par's Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Par's ANDA for 30 months.
January 15, 2015
16:32 EDTHCLPHi-Crush Partners raises Q4 dividend 8% to 67.5c
Subscribe for More Information
January 14, 2015
08:33 EDTDNDNDendreon says achieved cash-flow break even in Q4
Dendreon Corporation announced that the company grew sales in four quarters successively, exceeded its revenue target for the first time ever, and achieved cash-flow break even in Q4, starting 2015 on a strong footing. In addition, the first commercial European patient initiated treatment with PROVENGE in Germany the first country outside of the U.S. to offer the novel immunotherapy for advanced prostate cancer since receiving marketing authorization in the EU in 2013. Dendreon finished 2014 strong with a net product revenue for the year ended December 31, 2014 of $303.8M compared to $283.7M for the year ended December 31, 2013. Net product revenue for the fourth quarter ended December 31, 2014 was $79.8 million compared to $74.8 million for Q4. As of December 31, 2014, Dendreon had approximately $122M in cash, cash equivalents, and short-term and long-term investments. In early January, the first commercial patient in Germany began treatment with PROVENGE for advanced prostate cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use